Otonomy, Inc. Logo
Otonomy Reports Third Quarter 2016 Financial Results and Provides Corporate Update
03 nov. 2016 16h13 HE | Otonomy, Inc.
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy, Inc. Logo
Otonomy Announces Assignment of J Code for OTIPRIO®
02 nov. 2016 07h30 HE | Otonomy, Inc.
SAN DIEGO, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy to Report Third Quarter 2016 Financial Results and Provide Corporate Update
27 oct. 2016 16h05 HE | Otonomy, Inc.
SAN DIEGO, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy, Inc. Logo
Otonomy Holds Investor and Analyst Day and Provides Corporate Update
07 oct. 2016 08h00 HE | Otonomy, Inc.
SAN DIEGO, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy to Host Investor and Analyst Day on October 7, 2016
29 sept. 2016 07h30 HE | Otonomy, Inc.
SAN DIEGO, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy Announces OTIPRIO® Data Presentation and Symposium at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
13 sept. 2016 07h30 HE | Otonomy, Inc.
SAN DIEGO, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy, Inc. Logo
Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Ménière’s Disease Patients
01 août 2016 07h30 HE | Otonomy, Inc.
SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy to Report Second Quarter 2016 Financial Results and Provide Corporate Update
28 juil. 2016 16h30 HE | Otonomy, Inc.
SAN DIEGO, July 28, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy, Inc. Logo
Otonomy Reports First Quarter 2016 Financial Results and Provides Corporate Update
09 mai 2016 16h15 HE | Otonomy, Inc.
SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy to Present at the Bank of America Merrill Lynch Healthcare Conference
05 mai 2016 07h30 HE | Otonomy, Inc.
SAN DIEGO, May 05, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...